|
Riociguat for the treatment of pulmonary hypertension |
Tapia-López E, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A |
|
|
Citation Tapia-López E, Rey-Ares L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A. Riociguat for the treatment of pulmonary hypertension. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 475. 2016 Authors' conclusions Evidence of moderate methodological quality shows that riociguat, when compared with placebo, improves short-term functional capacity in patients with Functional Class II and III pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
No evidence was found assessing mortality or comparing riociguat with other widely used therapeutic alternatives of proven efficacy, safety and affordable costs.
The clinical practice guidelines reviewed mention its use and recommend to the extent they do with other existing treatments. The public health systems of Scotland, Wales and the United States as well as private U.S. health sponsors cover it.
Its high cost may limit the availability of this treatment.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Humans; Hypertension, Pulmonary; Pyrazoles; Pyrimidines Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001127 Date abstract record published 02/12/2016 |
|
|
|